Wednesday, August 1, 2018

British Journal of Cancer - Table of Contents alert Volume 119 Issue 3

If you are unable to see the message below, click here to view.
British Journal of Cancer


Explore the latest science, research, and clinical trials in hematology and oncology.

Volume 119, Issue 3

In this issue
Also new


Can we establish a hierarchy among trastuzumab biosimilar candidates?

Xavier Pivot & Thierry Petit

British Journal of Cancer 2018 119 :263 - 265; July 13, 2018; 10.1038/s41416-018-0171-1


Abstract | Full Text


Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer

Philip E. Lammers, Magdolna Dank, Riccardo Masetti, Richat Abbas, Fiona Hilton et al.

British Journal of Cancer 2018 119 :266 - 273; July 13, 2018; 10.1038/s41416-018-0147-1


Abstract | Full Text

Feasibility and acceptability of brief behavioral therapy for cancer-related insomnia: effects on insomnia and circadian rhythm during chemotherapy: a phase II randomised multicentre controlled trial

Oxana Palesh, Caroline Scheiber, Shelli Kesler, Michelle C. Janelsins, Joseph J. Guido et al.

British Journal of Cancer 2018 119 :274 - 281; July 20, 2018; 10.1038/s41416-018-0154-2


Abstract | Full Text

Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation

Frank Berthold, Angela Ernst, Barbara Hero, Thomas Klingebiel, Bernhard Kremens et al.

British Journal of Cancer 2018 119 :282 - 290; July 11, 2018; 10.1038/s41416-018-0169-8


Abstract | Full Text

A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin

Yi Zheng, Xiaoxuan Tu, Peng Zhao, Weiqin Jiang, Lulu Liu et al.

British Journal of Cancer 2018 119 :291 - 295; June 29, 2018; 10.1038/s41416-018-0138-2


Abstract | Full Text

Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer

Maren Knödler, Justus Körfer, Volker Kunzmann, Jörg Trojan, Severin Daum et al.

British Journal of Cancer 2018 119 :296 - 302; July 10, 2018; 10.1038/s41416-018-0150-6


Abstract | Full Text

Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials

Marc Peeters, Timothy Price, Julien Taieb, Michael Geissler, Fernando Rivera et al.

British Journal of Cancer 2018 119 :303 - 312; July 17, 2018; 10.1038/s41416-018-0165-z


Abstract | Full Text

Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease

Nikiana Simigdala, Sunil Pancholi, Ricardo Ribas, Elizabeth Folkerd, Gianmaria Liccardi et al.

British Journal of Cancer 2018 119 :313 - 322; July 11, 2018; 10.1038/s41416-018-0158-y


Abstract | Full Text

ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer

Antonia K. Roseweir, Elaine S. Halcrow, Sergey Chichilo, Arfon GMT Powell, Donald C. McMillan et al.

British Journal of Cancer 2018 119 :323 - 329; July 10, 2018; 10.1038/s41416-018-0174-y


Abstract | Full Text

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

Ilary Ruscito, Dan Cacsire Castillo-Tong, Ignace Vergote, Iulia Ignat, Mandy Stanske et al.

British Journal of Cancer 2018 119 :330 - 338; June 29, 2018; 10.1038/s41416-018-0157-z


Abstract | Full Text

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies

Nikolaus B Wagner, Andrea Forschner, Ulrike Leiter, Claus Garbe & Thomas K Eigentler

British Journal of Cancer 2018 119 :339 - 346; June 28, 2018; 10.1038/s41416-018-0167-x


Abstract | Full Text

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases

Heini M. L. Kallio, Reija Hieta, Leena Latonen, Anniina Brofeldt, Matti Annala et al.

British Journal of Cancer 2018 119 :347 - 356; July 10, 2018; 10.1038/s41416-018-0172-0


Abstract | Full Text

Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers

Inge A. P. Derks-Smeets, Lieske H. Schrijver, Christine E. M. de Die-Smulders, Vivianne C. G. Tjan-Heijnen, Ron J. T. van Golde et al.

British Journal of Cancer 2018 119 :357 - 363; June 25, 2018; 10.1038/s41416-018-0139-1


Abstract | Full Text

Proximity to overhead power lines and childhood leukaemia: an international pooled analysis

Aryana T Amoon, Catherine M Crespi, Anders Ahlbom, Megha Bhatnagar, Isabelle Bray et al.

British Journal of Cancer 2018 119 :364 - 373; May 29, 2018; 10.1038/s41416-018-0097-7


Abstract | Full Text

Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project

Giuseppe Gullo, Naomi Walsh, David Fennelly, Reetesh Bose, Janice Walshe et al.

British Journal of Cancer 2018 119 :374 - 380; May 18, 2018; 10.1038/s41416-018-0114-x


Abstract | Full Text

Comparison of anal cancer screening strategies including standard anoscopy, anal cytology, and HPV genotyping in HIV-positive men who have sex with men

Simon Pernot, Pauline Boucheron, Hélène Péré, Marie-Laure Lucas, David Veyer et al.

British Journal of Cancer 2018 119 :381 - 386; July 20, 2018; 10.1038/s41416-018-0176-9


Abstract | Full Text


Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma

Astrid Lièvre, Bérèngere Ouine, Jim Canet, Aurélie Cartier, Yael Amar et al.

British Journal of Cancer 2018 119 :387 - 387; June 14, 2018; 10.1038/s41416-018-0130-x


Abstract | Full Text

Correction: Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells

H Hirata, Y Hinoda, V Shahryari, G Deng, Y Tanaka et al.

British Journal of Cancer 2018 119 :388 - 388; June 22, 2018; 10.1038/s41416-018-0146-2


Abstract | Full Text

Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.

Click here to sign up.
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at: (You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved.

Springer Nature

No comments: